3079-LB: CMS-D008 Specifically Silences INHBE mRNA, Delivering Fat-Selective Weight Loss in Preclinical Study
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-3079-lb ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von JING JIA und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: Even though current approved anti-obesity medications have been proven to be effective for the treatment of overweight and obesity, limitations such as muscle mass loss and poor tolerability have subsequently emerged, promoting the development of next-generation therapies. Human genetics provides strong evidence supporting INHBE as a compelling target for sustainable weight management. Inhibiting INHBE could represent a novel and promising approach for long-term weight maintenance with favorable metabolic profiles.
Methods
CMS-D008 is a novel siRNA drug targeting INHBE administered via subcutaneous injection. The pharmacological effects of CMS-D008 were evaluated in humanized INHBE DIO mice and obese cynomolgus macaque models. Body weight, body composition, INHBE mRNA levels, and the target protein Activin E were assessed over the course of the studies.
Results
In humanized INHBE DIO mouse models, weekly administration of CMS-D008 (1, 3, and 9 mpk) significantly reduced hepatic INHBE mRNA expression and serum Activin E protein levels, leading to marked decreases in body weight, total body fat, and regional fat mass while preserving lean mass. In obese cynomolgus macaque models, CMS-D008 (1.5, 4.5, 10 mpk) administered on Days 1 and 29 significantly lowered plasma Activin E expression and effectively suppressed weight gain induced by a sustained high-fat diet.
Conclusion
CMS-D008 effectively reduced INHBE mRNA expression and lowered its gene product Activin E protein levels in both humanized INHBE DIO mice and obese cynomolgus macaque models. This target engagement promoted healthy weight loss by reducing fat mass while retaining lean mass. Disclosure J. Jia: Employee; Ended; Shenzhen Kangzhe Biotechnology Co., Ltd. J. Sun: None. Y. Wei: None. J. Zhang: None. Z. Zhu: None. T. Zhao: None. Q. Xu: None. L. He: None. D. Yang: None. R. Lu: Employee; Current; Shenzhen Kangzhe Biotechnology Co., Ltd.
Zitieren
APA
JIA, J., SUN, J., WEI, Y., ZHANG, J., ZHU, Z., ZHAO, T., XU, Q., HE, L., YANG, D., & LU, R. (2026). 3079-LB: CMS-D008 Specifically Silences INHBE mRNA, Delivering Fat-Selective Weight Loss in Preclinical Study. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-3079-lb
Vancouver
JIA J, SUN J, WEI Y, ZHANG J, ZHU Z, ZHAO T, et al. 3079-LB: CMS-D008 Specifically Silences INHBE mRNA, Delivering Fat-Selective Weight Loss in Preclinical Study. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-3079-lb
BibTeX
@article{JIA2026,
author = {JIA, JING and SUN, JING and WEI, YUTING and ZHANG, JINYANG and ZHU, ZHIFENG and ZHAO, TAO and XU, QIONG and HE, LIAN and YANG, DAZHOU and LU, RONG},
title = {3079-LB: CMS-D008 Specifically Silences INHBE mRNA, Delivering Fat-Selective Weight Loss in Preclinical Study},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-3079-lb}
}
EUVIMED